abbv-744
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 16, 2018 (NCT03360006)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Bromodomain-containing protein 2INHIBITOR
BRD2 inhibitor
- Bromodomain-containing protein 3INHIBITOR
BRD3 inhibitor
- BRD4/HDAC1INHIBITOR
BRD4/HDAC1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CCNC(=O)c1cc2c(-c3cc(C(C)(C)O)ccc3Oc3c(C)cc(F)cc3C)cn(C)c(=O)c2[nH]1- Mol. weight
- 491.56 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297454 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04454658 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2020 | AbbVie |
| NCT03360006 | Phase 1 | Mar 16, 2018 | AbbVie |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AbbVie | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1